Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road
Posted
Frank Vinluan (via MedCity News)
Caribou Biosciences is stopping work on its two remaining cancer cell therapies and exploring strategic alternatives for the business. The move follows the CRISPR biotech company’s failure to secure financing for its clinical trial plans.
The post Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road appeared first on MedCity News.